Medicare
Limited
Company at a Glance
The Big Picture: Ananta Medicare is a Delhi-incorporated pharmaceutical, nutraceutical, and ayurvedic manufacturer with three WHO-GMP and EU-GMP certified plants in Sri Ganganagar, Rajasthan. Founded in 1999 by Dr. Pradeep Kumar Jain, the company sells across 30+ countries, with exports constituting nearly 100% of revenue. FY25 marked a landmark year — revenue crossed ₹113 Cr, PAT more than doubled, and the company became virtually debt-free through a combination of internal cash generation and strategic capital raise. For pre-IPO investors, the headline numbers are extraordinary — but the business model carries a critical single-country concentration risk that must be stress-tested.
Industry Analysis
India's pharmaceutical industry is the world's third-largest by volume and 14th-largest by value. Total market size exceeds $50 Bn, with exports contributing ~$27 Bn. The CIS (Commonwealth of Independent States) is a strategically important export market for mid-sized Indian pharma companies — characterised by branded generics pricing, EU-GMP requirements for market access, and significantly higher realisations than Indian domestic or global tender markets. India's pharma export CAGR stands at approximately 8–11% over the last 5 years, with the CIS corridor growing faster due to regulatory tailwinds and Chinese supplier de-risking.
The CIS-focused Indian pharma export segment has relatively few organised players — Caplin Point Laboratories (LatAm + CIS), Cadila Pharmaceuticals (private, CIS), Alfa Healthcare, and a few others. EU-GMP certification for injectable manufacturing is a genuine barrier: less than 50 Indian plants hold active EU-GMP certification for sterile injectables. In the nutraceutical segment, Ananta competes with contract manufacturers supplying supplement brands globally — a more fragmented landscape where regulatory certifications (WHO GMP, ISO, HALAL) determine market access and pricing power.
Russia-Ukraine conflict has materially disrupted CIS pharmaceutical supply chains, banking channels, and regulatory continuity since 2022. While Ananta's revenue has actually grown through this period (a testament to relationship depth), the geopolitical overhang is not resolved. Currency volatility in Ukraine/CIS FX markets creates receivables collection risk. Rising input costs (API, packaging) and increased competition from other Indian manufacturers seeking CIS opportunities post-China de-risking could compress margins. US FDA absence limits Ananta's addressable market to regulated Western pharma — the world's most lucrative segment.
The global BIOSECURE Act momentum (US, EU) is driving pharma supply chain de-risking away from China — Indian manufacturers with GMP credentials are direct beneficiaries. Ukraine post-war reconstruction will require healthcare rebuilding — potentially opening order volumes beyond current levels if conflict resolves. New country registrations (South Africa-SAHPRA, Mexico-COFEPRIS) open large emerging markets. Nutraceutical global demand (gut health, immunity, women's health) is at multi-year highs, and Ananta's clinical study-backed portfolio (22 published studies) creates premium positioning. Lyophilized injectable segment (high-value, high-barrier) expansion is in pipeline.
Business Model
Manufacturing Infrastructure — Annual Capacity
Related Party Concentration: Ananta Medicare Ukraine Ltd. (related party, common shareholders with the Indian entity) accounted for ₹105.27 Cr (FY25) and ₹74.04 Cr (FY24) in sales — approximately 92.5% of consolidated revenue in both years. While the company classifies these as "undisputed and good" receivables, the concentration creates a single-point-of-failure risk that is material for any investment thesis evaluation.
Financial Story in Charts
Reading the story correctly: FY25 PAT of ₹39.40 Cr includes ₹5.28 Cr of forex gains (reported under Other Income). Adjusting for this, core operating PAT is approximately ₹34 Cr — implying a normalised PAT margin of ~30%. Additionally, the ₹10 Cr promoter licensing fee reduces reported profitability; absent this charge, post-tax NP margin would be approximately 43%. Investors should model both the reported and adjusted figures to understand the earnings quality. Equally important: despite ₹39.40 Cr PAT, operating cash flow was NEGATIVE (₹0.51 Cr outflow) — entirely due to ₹43.38 Cr receivables increase. Cash conversion is the critical watch metric.
Financial Snapshot (₹ Crore)
| Particulars | FY23 | FY24 | FY25 | YoY (FY25) | FY26E* |
|---|---|---|---|---|---|
| Revenue from Operations | 55.93 | 79.76 | 113.85 | +42.7% | ~142–150E |
| Revenue Growth % | Base yr | +42.6% | +42.7% | 2-yr CAGR: ~42.7% | ~25–30%E |
| Other Income (incl. forex gains) | 0.37 | 0.48 | 6.19 | +1,190% | ~2–3E |
| EBITDA (Operating) | 18.12 | 33.52 | 54.68 | +63.1% | ~65–72E |
| EBITDA Margin % | 32.4% | 42.0% | 48.0% | +600 bps | ~45–48%E |
| Depreciation & Amortisation | 7.13 | 7.17 | 7.26 | +1.3% | ~7–8E |
| Finance Cost | 0.56 | 0.29 | 0.62 | +113.8% | ~0.3E |
| Profit Before Tax | 10.80 | 26.54 | 52.99 | +99.7% | ~60–68E |
| Income Tax | 3.37 | 6.93 | 13.22 | +90.8% | — |
| Profit After Tax (Consolidated) | 7.43 | 19.61 | 39.77 | +102.8% | ~45–50E |
| PAT Margin % | 13.3% | 24.6% | 34.9% | +1,030 bps | ~30–33%E |
| PAT Growth % | Base yr | +163.9% | +102.8% | 2-yr CAGR: ~131.4% | ~13–25%E |
| EPS — Restated (₹)† | 1.06 | 2.80 | 5.60 | +100% | ~6.40–7.10E |
| Return on Equity % | — | 25% | 28% | +300 bps | ~28–32%E |
| ROCE % | — | 34% | 38% | +400 bps | ~36–40%E |
| Trade Receivables (₹ Cr) | — | 38.58 | 81.96 | +112.4% | Watch closely |
| Net Debt (₹ Cr) | — | 10.03 | ~0 (debt-free) | Eliminated | Debt-free |
† EPS for FY23–FY24 restated for share sub-division (₹100→₹10 FV) + 3:4 bonus issue completed in FY25. E = UnlistedZone estimates. FY26E EPS assumes normalised other income (~₹2–3 Cr). Source: AOC-4 (XBRL) Filings, Audited Consolidated P&L — MCA/Screener.in.
Cash Flow Warning: Despite ₹39.40 Cr PAT, operating cash flow was NEGATIVE at ₹0.51 Cr in FY25 (FY24: also negative at ₹4.21 Cr). The culprit: trade receivables increased by ₹43.38 Cr during the year — almost entirely attributable to the Ukrainian buyer. The company funded operations through ₹11.38 Cr financing activities (mainly the preferential allotment). Cash conversion cycle monitoring is essential; if receivables don't normalise in FY26, the company will need external funding despite strong P&L performance.
Quality Scorecard
Growth Metrics (2-yr CAGR FY23–FY25)
Quality Metrics (FY25)
Peer Comparison
| Company | Revenue (₹ Cr) | PAT (₹ Cr) | NP Margin | Mkt Cap (₹ Cr) | P/E (x) | Status |
|---|---|---|---|---|---|---|
| Ananta Medicare ★ | 113.85 | 39.77 | 34.9% | ~1,352 | ~34x | Pre-IPO |
| Caplin Point Labs | 2,187 | ~656 | ~30% | ~15,193 | ~24x | ✅ Listed |
| Marksans Pharma | 2,803 | ~364 | ~13% | ~9,401 | ~26x | ✅ Listed |
| Natco Pharma | 4,560 | ~1,550 | ~34% | ~21,477 | ~14x | ✅ Listed |
Valuation gap analysis: At 34x P/E, Ananta trades at a 40% premium to Caplin Point (24x) — despite being 20x smaller by revenue and 10x more geographically concentrated. The premium is partially justified by higher margins (34.6% vs Caplin's ~30%) and faster growth (+42.7% vs Caplin's typical 12–18%). However, Caplin Point operates across Latin America and CIS with genuine diversification — the two are not directly comparable risk profiles. The more apt comparison may be Natco Pharma (34% margins, 14x P/E with US FDA assets and diversified revenue) — which suggests Ananta's current valuation reflects significant optimism for future diversification.
Key Risks
Outlook & Key Triggers to Watch